# Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer

> **NCT01184326** · PHASE1 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 23 (actual)

## Conditions studied

- Solid Tumor
- Kidney Cancer

## Interventions

- **DRUG:** pazopanib
- **DRUG:** everolimus

## Key facts

- **NCT ID:** NCT01184326
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2019-10-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01184326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01184326, "Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01184326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*